BRD4 and melanoma: This study highlights complex 12 as a robust theranostic platform for real-time BRD4 imagingand inhibitor discovery, leveraging the photophysical advantages ofiridium­(III) to overcome the limitations of fluorescence-based screens.The repurposing of azelastine further highlights the potential ofmetallodrugs in targeting PPIs for cancer therapy, offering a pathwayto accelerate drug development for aggressive malignancies like melanoma.